Immunocore Holdings Reports $106.7 Million Revenue in Q1 2026, Driven by KIMMTRAK Sales

Immunocore Holdings plc reported a net revenue of $106.7 million for the first quarter of 2026, marking a 13.6% increase from $93.9 million in the same period of 2025. This growth was primarily driven by increased sales of its lead product, KIMMTRAK, particularly in the United States, where revenue rose to $67.4 million from $56.6 million year-over-year. The company also noted revenue contributions from Europe and international markets, which totaled $34.4 million and $4.8 million, respectively. Despite the increase in revenue, Immunocore continues to face significant operating losses, reporting a net income of $12.97 million for the quarter, compared to $5.02 million in the prior year.

In terms of operational metrics, Immunocore's total assets increased slightly to $1.072 billion as of March 31, 2026, up from $1.067 billion at the end of 2025. The company’s cash and cash equivalents decreased to $452.7 million from $467.7 million, while marketable securities also saw a slight decline. The company’s accumulated deficit improved to $818.3 million from $831.3 million, reflecting its ongoing efforts to manage expenses while expanding its product offerings. Research and development expenses rose to $61.1 million, up from $56.5 million, driven by increased costs associated with clinical trials and employee-related expenses.

Strategically, Immunocore has made significant advancements in its product pipeline, particularly with KIMMTRAK, which is now approved in 39 countries and commercially launched in over 30. The company is also progressing with its clinical programs, including a pivotal Phase 3 trial that demonstrated a five-year overall survival benefit for KIMMTRAK in patients with unresectable or metastatic uveal melanoma. The trial results, presented at the American Association for Cancer Research meeting, highlighted a doubling of the likelihood of survival at five years compared to the control group.

Looking ahead, Immunocore anticipates continued investment in research and development, particularly as it seeks to expand KIMMTRAK's market presence and advance other product candidates through clinical trials. The company expects to incur significant operating losses in the near future, necessitating additional funding to support its growth strategy. As of March 31, 2026, Immunocore's working capital stood at $763.7 million, providing a buffer for ongoing operations, although the company acknowledges the potential need for further financing to sustain its long-term objectives.